NRG
ACAD icon

Nemes Rush Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Nemes Rush Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$44.5K Hold
2,000
– – ﹤0.01% 371
2025
Q4 		$53.4K Hold
2,000
– – 0.01% 339
2025
Q3 		$42.7K Hold
2,000
– – ﹤0.01% 346
2025
Q2 		$43.1K Hold
2,000
– – ﹤0.01% 349
2025
Q1 		$33.2K Hold
2,000
– – ﹤0.01% 361
2024
Q4 		$36.7K Hold
2,000
– – ﹤0.01% 339
2024
Q3 		$37K Hold
2,000
– – 0.01% 295
2024
Q2 		$32.5K Hold
2,000
– – ﹤0.01% 303
2024
Q1 		$37K Hold
2,000
– – 0.01% 320
2023
Q4 		$62.6K Hold
2,000
– – 0.01% 243
2023
Q3 		$41.7K Hold
2,000
– – 0.01% 272
2023
Q2 		$47.9K Buy
+2,000
New +$44.5K 0.01% 268

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return